Preclinical Pharmacokinetic/Pharmacodynamic Modeling and Simulation in the Pharmaceutical Industry: An IQ Consortium Survey Examining the Current Landscape
| Autor: | Majid Vakilynejad, Arijit Chakravarty, Tonika Bohnert, Anu Shilpa Krishnatry, Jerome T. Mettetal, Tristan S. Maurer, Christopher R. Gibson, Daniel R. Mudra, Edgar Schuck, Yaming Su, Marjoleen J.M.A Nijsen, Tycho Heimbach, Shining Wang, Virna J A Schuck, Cheng-Pang Hsu, Harvey Wong, Patrick Trapa, Joseph Raybon, Patricia Schroeder, Satyendra Suryawanshi, Jing Lin, Bianca M. Liederer, Valeriu Damian-Iordache, Alice Tsai |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Drug
Discussion Dose-Response Relationship Drug Drug Industry business.industry Pharmacokinetic pharmacodynamic Data Collection media_common.quotation_subject Drug Evaluation Preclinical Pharmaceutical Science Pharmacy Pharmacology Models Biological Pharmacokinetics Drug development Therapeutic Area Drug Design Pharmacodynamics Drug Discovery Humans Medicine Computer Simulation business Pharmaceutical industry media_common |
| Zdroj: | The AAPS Journal. 17:462-473 |
| ISSN: | 1550-7416 |
| Popis: | The application of modeling and simulation techniques is increasingly common in preclinical stages of the drug discovery and development process. A survey focusing on preclinical pharmacokinetic/pharmacodynamics (PK/PD) analysis was conducted across pharmaceutical companies that are members of the International Consortium for Quality and Innovation in Pharmaceutical Development. Based on survey responses, ~68% of companies use preclinical PK/PD analysis in all therapeutic areas indicating its broad application. An important goal of preclinical PK/PD analysis in all pharmaceutical companies is for the selection/optimization of doses and/or dose regimens, including prediction of human efficacious doses. Oncology was the therapeutic area with the most PK/PD analysis support and where it showed the most impact. Consistent use of more complex systems pharmacology models and hybrid physiologically based pharmacokinetic models with PK/PD components was less common compared to traditional PK/PD models. Preclinical PK/PD analysis is increasingly being included in regulatory submissions with ~73% of companies including these data to some degree. Most companies (~86%) have seen impact of preclinical PK/PD analyses in drug development. Finally, ~59% of pharmaceutical companies have plans to expand their PK/PD modeling groups over the next 2 years indicating continued growth. The growth of preclinical PK/PD modeling groups in pharmaceutical industry is necessary to establish required resources and skills to further expand use of preclinical PK/PD modeling in a meaningful and impactful manner. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink